Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Stopped early · Phase 2

Conditions studied: Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma

In brief

The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.

Key facts

Study ID: NCT04788043
Run by: Ranjana Advani
People needed: 8
Starts: 2022-06-21
Expected to finish: 2025-08-29
Last updated by the study team: 2026-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Biopsy proven relapsed or refractory cHL
Prior treatment with at least two systemic therapies
Metabolically active measurable disease by PET imaging per the 2014 Lugano criteria
Hemoglobin ≥ 9.5 g/dL
Absolute neutrophil count ≥ 1,000 cells/μL without G-CSF support within 3 weeks prior to enrollment
Platelet count ≥ 75,000 cells/μL
Creatinine clearance > 40 mL/min per the Cockroft-Gault formula
Total bilirubin < 1.5 x upper limit of normal (ULN) (or < 3.0 x ULN and primarily unconjugated in subjects with a history of Gilbert's syndrome)
Negative urine or serum pregnancy test within 30 days of enrollment and within 72 hours before the first administration of magrolimab for women of childbearing potential
Women of childbearing potential must be willing to use at least 1 highly effective method of contraception during the study and continue for 4 months after the last dose of magrolimab
Male subjects who are sexually active with a woman of childbearing potential and who have not had vasectomies must be willing to use a barrier method of contraception during the study and for 4 months after the last dose of magrolimab
Ability to understand and the willingness to sign the written IRB approved informed consent document
Must be willing and able to comply with the clinic visits and procedures outlined in the study protocol

You may not qualify if…

Prior treatment with a PD-1 inhibitor within 3 months prior to enrollment
Prior treatment with antibodies targeting CD47 or SIRPα2
Prior allogeneic hematopoietic cell transplantation
Systemic autoimmune disorder on chronic immunosuppression (defined as ≥ 10 mg of prednisone daily)
RBC transfusion dependence, defined as requiring more than 2 units of RBCs during the 4-week period prior to screening
History of hemolytic anemia, autoimmune thrombocytopenia, or Evan's syndrome within the last 3 months
Second malignancy not in complete remission for at least 1 year, excluding fully resected non melanoma skin cancer or localized prostate cancer
Women who are pregnant or breast feeding
HIV or hepatitis B or C infection with active viral replication by PCR
Second malignancy not in complete remission for at least 1 year, excluding fully resected non-melanoma skin cancer or localized prostate cancer
Active cardiac disease including unstable angina, decompensated congestive heart failure, or severe uncontrolled conduction abnormalities
History of non-infectious pneumonitis requiring corticosteroids or current pneumonitis
Significant medical conditions, as assessed by the investigators and IND holder, that would substantially increase the risk benefit ratio of participating in the study
History of psychiatric illness or substance abuse likely to interfere with ability to comply with protocol requirements
Received a live or live attenuated vaccine within 30 days before the first dose of study intervention
Received any anti-cancer therapy within 2 weeks prior to the first dose of study intervention

Where it is running

Stanford University — Stanford, California, United States
Dana Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.